share_log

港股异动 | 艾美疫苗飙升逾140%，获纳入港股通于今日生效，市场猜测公司布局A股IPO

Changes in Hong Kong stocks | Le Meridien's vaccine soared more than 140% and was included in the Hong Kong Stock Exchange Pass effective today. The market speculates that the company will lay out an A-share IPO

Zhitong Finance ·  Mar 13, 2023 09:42

Zhitong Financial APP learned that$AIM VACCINE (06660.HK)$It surged more than 140 per cent in early trading with a turnover of more than HK $4 million.

On the face of the news, Amy Vaccine was recently included in the first batch of newly transferred stocks of the Shanghai-Hong Kong Stock Connect and the Hang Seng Composite Index, effective from March 13, 2023.

In addition, the company intends to issue no more than 242 million unlisted RMB common shares, accounting for about 20 per cent of the total number of issued shares. The fund-raising will be used for the research and development of EV71-CA16 bivalent hand, foot and mouth disease and COVID-19 mRNA vaccine. Some market participants believe that the exit channel for the shares issued by Amy Vaccine in the future will be the A-share market. Therefore, this news is also seen by some investors as a prelude to Amy Vaccine layout A-share IPO.

Edit / Somer

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment